KR970701557A - 자기면역성 질환의 치료 수단 및 치료 방법(means for treating auto-immune diseases and method of treatment) - Google Patents

자기면역성 질환의 치료 수단 및 치료 방법(means for treating auto-immune diseases and method of treatment) Download PDF

Info

Publication number
KR970701557A
KR970701557A KR1019960705237A KR19960705237A KR970701557A KR 970701557 A KR970701557 A KR 970701557A KR 1019960705237 A KR1019960705237 A KR 1019960705237A KR 19960705237 A KR19960705237 A KR 19960705237A KR 970701557 A KR970701557 A KR 970701557A
Authority
KR
South Korea
Prior art keywords
glucoprotein
trophoblast
treatment
treating
immune diseases
Prior art date
Application number
KR1019960705237A
Other languages
English (en)
Other versions
KR100382252B1 (ko
Inventor
세묘노비치 타타리노프 주리
압두무슬리모비치 알리카노프 칼라
Original Assignee
이반 니콜라에비치 골로비스티코프
레오니드 야조노비치 카차라바
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이반 니콜라에비치 골로비스티코프, 레오니드 야조노비치 카차라바 filed Critical 이반 니콜라에비치 골로비스티코프
Publication of KR970701557A publication Critical patent/KR970701557A/ko
Application granted granted Critical
Publication of KR100382252B1 publication Critical patent/KR100382252B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • External Artificial Organs (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

본 발명은 억제 면역결여를 보이는 자기번역성 질환을 치료하기 위한 수단으로서 사용되는 영양막 β-I-글루코프로테인에 관한다.
또한, 본 발명은, 단핵세포(MNC)의 TBG 민감성 시험과 관령되는 영양막 β-I-글루코프로테인(TBG)의 면역 보정제의 투여를 포함하는 자기면역성 질환의 치료방법에 관한 것이다.

Description

자기면역성 질환의 치료 수단 및 치료 방법(MEANS FOR TREATING AUTOIMMUNE DISEASES AND METHOD OF TREATMENT)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 자기면역성 질환을 치료하기 위한 수단으로서 사용되는 영양막 β-I-글루코프로테인(TBG).
  2. 면역상태를 사전연구하여, 억제자 결여가 발견되는 경우, 이어서 면역 보정제로서 영양막 β-I-글루코프로테인을 혈액 1ml당 3 내지 120㎍의 투여량으로 주입되는 것을 특징으로 하는, 면역 보정제를 주입시키는 것을 포함하는 자기면역성 질환의 치료방법.
  3. 제2항에 있어서, 영양막 β-I-글루코프로테인이 비경구적으로 주입되는 것을 특징으로 하는 방법.
  4. 제2항에 있어서, 60㎍/㎖ 농도의 영양막 β-I-글루코프로테인은 말초혈로부터 단리된 자기면역 세포와 배양되어, 정맥내로 주입되는 것을 특징으로 하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960705237A 1994-03-18 1995-03-16 자가면역성질환을치료하기위한약제조성물 KR100382252B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU9494008169A RU2056852C1 (ru) 1994-03-18 1994-03-18 Средство для лечения аутоиммунных заболеваний с иммунодефицитом супрессоров и способ лечения аутоиммунных заболеваний
RU94008169 1994-03-18

Publications (2)

Publication Number Publication Date
KR970701557A true KR970701557A (ko) 1997-04-12
KR100382252B1 KR100382252B1 (ko) 2003-07-07

Family

ID=20153349

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960705237A KR100382252B1 (ko) 1994-03-18 1995-03-16 자가면역성질환을치료하기위한약제조성물

Country Status (22)

Country Link
US (1) US6150326A (ko)
EP (1) EP0790059B1 (ko)
JP (1) JPH09510473A (ko)
KR (1) KR100382252B1 (ko)
CN (1) CN1146156A (ko)
AT (1) ATE260111T1 (ko)
AU (1) AU699896B2 (ko)
BG (1) BG62759B1 (ko)
CA (1) CA2185892A1 (ko)
CZ (1) CZ285856B6 (ko)
DE (2) DE790059T1 (ko)
ES (1) ES2107980T1 (ko)
FI (1) FI963671A (ko)
GE (1) GEP20012377B (ko)
GR (1) GR980300023T1 (ko)
HU (1) HUT75720A (ko)
NO (1) NO963911L (ko)
PL (1) PL179765B1 (ko)
RU (1) RU2056852C1 (ko)
SK (1) SK281948B6 (ko)
UA (1) UA26939C2 (ko)
WO (1) WO1995025531A1 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0030729D0 (en) * 2000-12-16 2001-01-31 Univ Nottingham Substituted-4-Quinolones
CA2501940A1 (en) * 2002-10-09 2004-04-22 Tolerrx, Inc. Molecules preferentially associated with effector t cells or regulatory t cells and methods of their use
RU2303995C1 (ru) * 2006-04-28 2007-08-10 Халлар Абдумуслимович Алиханов Средство, обладающее иммунорегуляторным свойством и его применение для лечения аутоиммунных заболеваний

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5470384A (en) * 1977-08-22 1979-06-06 Inst Obu Kiyansaa Risaachi Roi High molecular complex
JPS61186322A (ja) * 1985-02-13 1986-08-20 Nippon Univ 免疾調節剤
IT1188646B (it) * 1986-04-09 1988-01-20 Ellem Ind Farmaceutica Tripeptide ad attivita' immunostimolante
US4803072A (en) * 1986-09-10 1989-02-07 Smithkline Beckman Corporation Immunomodulation
FR2609632B1 (fr) * 1987-01-21 1991-03-29 Shelly Marc Nouvelle application therapeutique de la 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinon-6-one et les compositions pharmaceutiques destinees a cet usage
US5169835A (en) * 1989-01-18 1992-12-08 Oklahoma Medical Research Foundation Pregancy specific proteins applications
FR2650183A1 (fr) * 1989-07-25 1991-02-01 Pasteur Institut Proteines immunostimulantes, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et application de ces produits a des fins therapeutiques et de diagnostic
US5118669A (en) * 1989-09-20 1992-06-02 Hitachi Chemical Co., Ltd. Peptides and intermediates therefor useful as antiallergic agents, vasodilators and immunoregulators
US5559097A (en) * 1990-01-12 1996-09-24 Idaho Research Foundation, Inc. Use of a pregnancy specific protein as an immunosuppressive
RU1836957C (ru) * 1990-03-25 1993-08-30 2-й Московский государственный медицинский институт им.Н.И.Пирогова Способ получени трофобластического бета @ -гликопротеина
GB2251186A (en) * 1990-12-04 1992-07-01 Randall Neal Gatz Polypeptide for use in treatment of autoimmune disease

Also Published As

Publication number Publication date
BG62759B1 (bg) 2000-07-31
WO1995025531A1 (fr) 1995-09-28
RU2056852C1 (ru) 1996-03-27
KR100382252B1 (ko) 2003-07-07
US6150326A (en) 2000-11-21
SK118796A3 (en) 1997-06-04
AU699896B2 (en) 1998-12-17
CN1146156A (zh) 1997-03-26
ATE260111T1 (de) 2004-03-15
PL179765B1 (pl) 2000-10-31
DE69532611D1 (de) 2004-04-01
FI963671A0 (fi) 1996-09-17
AU2087495A (en) 1995-10-09
NO963911D0 (no) 1996-09-18
BG100921A (en) 1997-12-30
GEP20012377B (en) 2001-03-25
PL316311A1 (en) 1997-01-06
EP0790059A1 (en) 1997-08-20
DE790059T1 (de) 1998-03-12
JPH09510473A (ja) 1997-10-21
CZ285856B6 (cs) 1999-11-17
NO963911L (no) 1996-11-08
HUT75720A (en) 1997-05-28
GR980300023T1 (en) 1998-04-30
UA26939C2 (uk) 1999-12-29
ES2107980T1 (es) 1997-12-16
EP0790059B1 (en) 2004-02-25
CZ274796A3 (en) 1997-06-11
HU9602558D0 (en) 1996-11-28
SK281948B6 (sk) 2001-09-11
EP0790059A4 (en) 2000-11-02
FI963671A (fi) 1996-11-14
CA2185892A1 (en) 1995-09-28

Similar Documents

Publication Publication Date Title
Ahlgren et al. Mechanical hyperalgesia in streptozotocin-diabetic rats
KR960033460A (ko) 심장의 염증성 질병 치료용 약제학적 조성물
Roch-Arveiller et al. Tachykinins: effects on motility and metabolism of rat polymorphonuclear leucocytes
BR0105308A (pt) Filtro para combustìvel de motor a diesel
DE3889536D1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
Salton et al. Subunit structure and properties of two forms of adenosine triphosphatase released from Micrococcus, lysodeikticus membranes
ATE312909T1 (de) Diagnostika und behandlungen von peridontalen erkrankungen
BR9808221A (pt) Método de tratamento de tumor.
DaVanzo et al. Inhibition of isolation-induced aggressive behavior with GABA transaminase inhibitors
KR970701557A (ko) 자기면역성 질환의 치료 수단 및 치료 방법(means for treating auto-immune diseases and method of treatment)
ES2109234T3 (es) Metodo de tratamiento de la uveorretinitis autoinmune en el hombre.
Harari et al. Ileal mucosal response to bacterial toxin challenge
KR960705578A (ko) 경증 질환을 가진 b형 간염 보균자의 치료방법(method for treating hepatitis b carriers with minimal disease)
KR920021144A (ko) 역류성 식도염을 치료하기위한 니자티딘의 용도
ATE178074T1 (de) Proinsulin-peptid-verbindungen für den nachweis und die behandlung von typ-i-diabetes
DK0972032T3 (da) Peptider til behandling af systemisk lupus erythematosus
Pabello et al. Neuroimmunotoxicology: Modulation of neuroimmune networks by toxicants
EA199800821A1 (ru) Способ лечения аутизма
Aldenborg Thymus dependence of compound 48/80-induced mucosal mast cell proliferation
Ryan Regulation of the free amino acids of skin by hydrocortisone
Sesack et al. Synaptie input from opioid terminals to dopamiiiergic and non-dopaminergic neurons in the ventral tegmental area of the rat
BG101325A (en) Use of muramyl peptide compounds
Kanayama et al. Involvement of sympathetic nervous system inhibition in the hypotensive effect of bromocriptine in spontaneously hypertensive rats
EA200300222A1 (ru) Лечение гепатита c с помощью тимозина, интерферона и рибавирина
Gately et al. Effect of anti-lymphotoxin on cell-mediated cytotoxicity: Evidence for two pathways of cytolysis

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee